Wasatch Advisors Inc. Trims Stake in AtriCure, Inc. (ATRC)
Wasatch Advisors Inc. decreased its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC) by 3.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 423,963 shares of the medical device company’s stock after selling 13,341 shares during the period. Wasatch Advisors Inc. owned approximately 1.23% of AtriCure worth $9,484,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also bought and sold shares of ATRC. Neuberger Berman Group LLC boosted its position in shares of AtriCure by 45.5% during the 2nd quarter. Neuberger Berman Group LLC now owns 824,469 shares of the medical device company’s stock valued at $19,993,000 after purchasing an additional 257,949 shares in the last quarter. Cortina Asset Management LLC boosted its holdings in shares of AtriCure by 101.4% in the third quarter. Cortina Asset Management LLC now owns 440,072 shares of the medical device company’s stock worth $9,844,000 after buying an additional 221,605 shares during the period. FMR LLC boosted its holdings in shares of AtriCure by 2.4% in the second quarter. FMR LLC now owns 5,068,247 shares of the medical device company’s stock worth $122,905,000 after buying an additional 118,247 shares during the period. Vanguard Group Inc. boosted its holdings in shares of AtriCure by 5.7% in the first quarter. Vanguard Group Inc. now owns 1,393,971 shares of the medical device company’s stock worth $26,695,000 after buying an additional 75,266 shares during the period. Finally, Quantum Capital Management acquired a new position in shares of AtriCure in the third quarter worth about $1,053,000. Institutional investors own 87.87% of the company’s stock.
Several brokerages have commented on ATRC. ValuEngine cut shares of AtriCure from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th. Canaccord Genuity decreased their target price on shares of AtriCure from $28.00 to $24.00 and set a “buy” rating for the company in a report on Thursday, November 2nd. Needham & Company LLC decreased their target price on shares of AtriCure from $26.00 to $25.00 and set a “buy” rating for the company in a report on Thursday, November 2nd. Zacks Investment Research upgraded shares of AtriCure from a “sell” rating to a “hold” rating in a report on Monday, October 2nd. Finally, BidaskClub cut shares of AtriCure from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $25.00.
In other AtriCure news, Director B Kristine Johnson acquired 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The shares were purchased at an average price of $18.36 per share, with a total value of $27,540.00. Following the completion of the transaction, the director now owns 10,969 shares in the company, valued at $201,390.84. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 10.00% of the stock is currently owned by company insiders.
AtriCure, Inc. (ATRC) traded down $0.11 during mid-day trading on Thursday, hitting $18.07. 204,800 shares of the company traded hands, compared to its average volume of 199,761. The company has a quick ratio of 1.65, a current ratio of 2.28 and a debt-to-equity ratio of 0.20. AtriCure, Inc. has a twelve month low of $14.78 and a twelve month high of $25.18.
AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Wednesday, November 1st. The medical device company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.02. The firm had revenue of $42.20 million for the quarter, compared to analyst estimates of $43.44 million. AtriCure had a negative net margin of 19.40% and a negative return on equity of 20.28%. The company’s revenue for the quarter was up 10.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.21) earnings per share. analysts anticipate that AtriCure, Inc. will post -0.96 earnings per share for the current year.
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.